Telomeres & Cell Immortalization Program

Telomeres & Cell Immortalization Program

Xuefeng Liu, MD
Professor of Pathology

Dr. Xuefeng Liu in his lab

Dr. Liu is a Professor in the Department of Pathology, serves as Director of Telomeres and Cell Immortalization Program, and Scientific Director of Conditional Reprogramming Laboratory (CRL) within the CCR. Dr. Liu’s research interests focus on the roles of papillomavirus oncoproteins and telomerase in cell immortalization which is a very early stage of human cancer. Together with Dr. Schlegel, Dr. Liu recently co-invented a new cell technology, CRC technology, which was described in the Journal of Clinical Investigation (2010), American Journal of Pathology (2012, 2013), New England Journal of Medicine (2012), PNAS (2012), PLoS One (2014) and Oncotarget (2014). This technology allows us to rapidly propagate patient-derived normal and tumor (diseased) cells infinitely. Importantly, he utilized this technology to identify Infection of HPV 11 and an effective therapy for a patient with metastatic pulmonary tumors arising from laryngeal papillomatosis. These results represent the first successful example of individualized therapy (NEJM). Dr. Liu has trained more than 50 researchers from NIH/universities–Harvard, Yale, Duke, Stanford, Arizona, Wake Forest, UNC, Thomas Jefferson, CUHK, Mayo, MD Anderson to name a few–as well as scientists at Georgetown University to use CRC technique in their research. This training also resulted in a broad spectrum of intramural and extramural collaborations. Currently, Dr. Liu is leading the program of Cell Immortalization and direct (Scientific) Conditional Reprogramming Laboratory (CRL) together with Dr. Ewa Krawczyk. He currently serves as an Academic Editor of PLoS ONE and as a board member of Virus Genes, and as a reviewer for PNAS, Cancer Research, Nucleic Acid Research, Journal of Virology, International Journal of Cancer, International Journal of Biochemistry and Cell Biology, Journal of Cellular and Molecular Medicine, Carcinogenesis, PLoS One, Molecular Cancer Research and Gynecologic Oncology. Dr. Liu obtained his medical and biochemistry training in China and postdoctoral training with Dr. Raymond Schinazi at Emory University and Dr. Thomas Zheng at National Cancer Institute (NCI), respectively.